Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Taccone, Fabio S ^a   Laterre, Pierre François ^b   Spapen, Herbert ^c   Dugernier, Thierry ^d   Delattre, Isabelle ^e   Layeux, Brice ^a   De Backer, Daniel ^a   Wittebole, Xavier ^b   Wallemacq, Pierre ^e   Vincent, Jean Louis ^a   Jacobs, Frédérique ^a  

^a ERASME HOSPITAL   (Belgium)

^b Department of Intensive Care ^*  (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d Clinique Saint Pierre of Ottignies   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BELGIUM; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROBACTERIACEAE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTIC SHOCK; AGED; BLOOD; DOSE RESPONSE; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; BELGIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 77950524429     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8945     Document Type: Article

References (51)

1. Vincent JL, Taccone F, Schmit X. Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib Nephrol 2007, 156:64-74. full_text, 17464116.
2. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. 10.1378/chest.115.2.462, 10027448.
3. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9:412-418. 10.1046/j.1469-0691.2003.00656.x, 12848754.
4. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007, 13:592-597. 10.1097/MCC.0b013e32827851d7, 17762241.
5. Bochud PY, Glauser MP, Carlet J, Calandra T. Empirical antibiotic therapy for patients with severe sepsis and septic shock. The Sepsis Text 2002, 539-558. Norwell: Kluwer Academic, Vincent JL, Carlet J, Opal SM.
6. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527. 10.1016/S1473-3099(04)01108-9, 15288826.
7. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006, CD003344.
8. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984, 149:443-448.
9. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984, 77:657-662. 10.1016/0002-9343(84)90358-9, 6385693.
10. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
11. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986, 5:319-324.
12. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, 30:134-144.
13. EUCAST Aminoglycosides: EUCAST clinical MIC breakpoints. EUCAST., http://wwwsrgaorg/eucastwt/MICTAB/MICaminoglycosideshtml
14. Fukuoka N, Aibiki M. Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance. J Clin Pharm Ther 2008, 33:521-527. 10.1111/j.1365-2710.2008.00947.x, 18834367.
15. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991, 27(Suppl C):91-103.
16. Marik PE, Havlik I, Monteagudo FS, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991, 27(Suppl C):81-89.
17. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997, 25:806-811. 10.1097/00003246-199705000-00016, 9187600.
18. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008, 30:674-681. 10.1097/FTD.0b013e31818b6b2f, 19057371.
19. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
20. Gilbert DN. Aminoglycosides. Principle and Practice in Infectious Diseases 2000, 307-336. New York: Churchill Livingstone, Mandell GL, Bennett JE, Dolin R.
21. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629. 89170, 10049277.
22. Devine BJ. Gentamicin therapy. Drug Intel Clin Pharm 1974, 8:650-655.
23. Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980, 37:519-522.
24. Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995, 39:545-548. 162577, 7726530.
25. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007, 27:1081-1091. 10.1592/phco.27.8.1081, 17655508.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
27. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
28. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332. 10.1016/j.ajic.2008.03.002, 18538699.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
30. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. 10.1097/CCM.0b013e3181961bff, 19237886.
31. Zaske DE, Sawchuk RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976, 16:824-828. 10.1097/00005373-197610000-00014, 994263.
32. Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother 1987, 31:1855-1858. 175054, 3435131.
33. Van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990, 16(Suppl 3):S235-S238. 10.1007/BF01709707, 2289997.
34. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003, 51:347-352. 10.1093/jac/dkg102, 12562701.
35. Holford N. Clinical Pharmacokinetics: Drug Data Handbook 1998, Auckland: Adis, 3.
36. Oparaoji EC, Cornwell EE, Hekmat E, Lum CR, Adir JS, Siram S. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993, 12:131-134.
37. Botha FJ, Bijl P, Seifart HI, Parkin DP. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996, 22:443-446. 10.1007/BF01712162, 8796397.
38. Kihara M, Ikeda Y, Takagi N, Fujita H, Shibata K, Masumori S, Shiratori K, Umemura S, Shionoiri H, Ishii M. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Intensive Care Med 1995, 21:348-351. 10.1007/BF01705414, 7650258.
39. Lugo-Goytia G, Castaneda-Hernandez G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000, 34:1389-1394.
40. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003, 114:194-198. 10.1016/S0002-9343(02)01476-6, 12637133.
41. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800. 10.1007/s10096-007-0371-8, 17701063.
42. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002, 28:936-942. 10.1007/s00134-002-1313-7, 12122533.
43. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993, 21:172-173.
44. Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 2003, 9:292-296. 10.1007/s10156-003-0279-x, 14691648.
45. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet 1994, 26:292-307. 10.2165/00003088-199426040-00005, 8013162.
46. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000, 39:215-231. 10.2165/00003088-200039030-00004, 11020136.
47. Bourguignon L, Goutelle S, Gerard C, Guillermet A, Burdin de Saint MJ, Maire P, Ducher M. [Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight]. Therapie 2009, 64:47-53. 10.2515/therapie/2009009, 19463252.
48. Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16:303-306. 10.1007/BF01706354, 2212254.
49. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034. 10.2165/00003088-200544100-00002, 16176116.
50. Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2010,
51. Anglemyer B, Hernandez C, Brice JH, Zou B. The accuracy of visual estimation of body weight in the ED. Am J Emerg Med 2004, 22:526-529. 10.1016/j.ajem.2004.09.002, 15666254.